The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China
Not yet recruiting
- Conditions
- CLL
- Registration Number
- NCT06489184
- Lead Sponsor
- Peking University People's Hospital
- Brief Summary
This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 490
Inclusion Criteria
-
- Patients aged ≥18 years old
-
- Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) requiring treatment (iwCLL [International Workshop on Chronic Lymphocytic Leukemia] criteria)；
-
- Treatment-naïve OR Refractory Recurrence CLL patients who were initiated on Zanubrutinib;
- 4.Prior or current use of Zanubrutinib for ≥3 months
- 5.At least one follow-up was recorded during Zanubrutinib treatment
Exclusion Criteria
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression Free Survival (PFS) up to two years PFS is defined as the duration from date of Zanubrutinib initiation to date of disease progression (PD \[according to the physician's evaluation\]) or death from any cause
- Secondary Outcome Measures
Name Time Method Adverse Events up to two years Percentage of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Special Situations
Overall Survival up to two years OS is defined as the time from the starting date of Zanubrutinib to the date of death due to any cause.
Time to Next Therapy (TTNT) up to two years The TTNT will be calculated as the difference between Zanubrutinib initiation date and initiation date of the first next therapy for CLL
Trial Locations
- Locations (1)
Peking University People's Hospital
🇨🇳Beijing, Beijing, China